Table 2.
Antibiotics sensitivity pattern of the MDR E. coli isolates
| S. no. | Antibiotics | Resistance (n = 77) | Sensitive | Intermediate |
|---|---|---|---|---|
| 1 | CL | 3.89% (3) | 96.1% (74) | 0 |
| 2 | IPM | 14.28% (11) | 80.51% (62) | 5.19% (4) |
| 3 | NIT | 24.67% (19) | 64.93% (50) | 10.38% (8) |
| 4 | CAC | 25.97% (20) | 64.93% (50) | 9.09% (7) |
| 5 | NET | 38.96% (30) | 54.54% (42) | 6.49% (5) |
| 6 | AK | 40.25% (31) | 53.24% (41) | 6.49% (5) |
| 7 | CFS | 46.75% (36) | 42.85% (33) | 10.38% (8) |
| 8 | GEN | 53.24% (41) | 42.85% (33) | 3.89% (3) |
| 9 | PIT | 55.84% (43) | 36.36% (28) | 7.79% (6) |
| 10 | COT | 67.53% (52) | 25.97% (20) | 3.89% (3) |
| 11 | AMC | 90.9% (70) | 9.09% (7) | 0 |
| 12 | OF | 93.5% (72) | 6.49% (5) | 0 |
| 13 | NX | 94.8% (73) | 5.19% (4) | 0 |
| 14 | CTR | 96.1% (74) | 2.59% (2) | 0 |
| 15 | CPM | 96.1% (74) | 2.59% (2) | 0 |
| 16 | CAZ | 100% (77) | 0 | 0 |
CL colistin, IPM imipenem, NIT nitrofurantoin, CAC ceftazidime/clavulanic acid, NET netilimicin, AK amikacin, CFS cefoperazone/sulbactum, GEN gentamicin, PIT piperacilin/tazobactun, COT co-trimoxazole, AMC amoxyclav, OF ofloxacin, NX norfloxacin, CTR ceftriaxone, CPM cefepime, CAZ ceftazidime